<DOC>
	<DOCNO>NCT01131065</DOCNO>
	<brief_summary>The aim clinical trial evaluate efficacy , safety , tolerability Niuliva ( Hepatitis B virus immune globulin ) prophylaxis hepatitis B virus ( HBV ) reinfection patient submit liver transplantation due HBV-induced liver disease reach maintain certain hepatitis B antibody ( HBsAg ) level consider protective first six twelve month post-transplantation .</brief_summary>
	<brief_title>Efficacy Safety Niuliva® Prevention Hepatitis B Virus Recurrence Newly Orthotopic Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Male female . Patients 18 70 year age ( include ) . Serum HBV DNAnegative determine DNA PCRamplification assay prior anhepatic phase visit . Serum HBeAg negative prior anhepatic phase visit . Patients undergo liver transplantation due liver disease associate HBV . The patient agree participate comply aspect protocol , include blood sampling , total duration study . Signed informed consent . Patients already experience liver transplantation even reason related HBV infection . Patients unknown serum HBV replication status ( data HBeAg HBV DNA ) . Patients known allergy component Niuliva® . History serious adverse event ( SAEs ) frequent adverse event ( AEs ) relate administration human bloodderived product . Patient unknown viral status HCV , HAV , HIV type 1 type 2 Patients selective IgA deficiency . Any haemostatic abnormality contraindicate i.v . injection accord investigator 's judgment . Patient suffers acute chronic medical , surgical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration , may interfere interpretation study result . Known abuse alcohol , drug chemical substance ; do past 6 month . Breastfeeding woman pregnant woman time inclusion expect pregnant within next 7 month inclusion . Subject participate investigational study within last 3 month . Existing possibility patient may treat product contain specific antihepatitis B immunoglobins ( Niuliva® ) period 13 month . Subject incapable give consent personally .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Orthotopic liver transplantation</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Reinfection</keyword>
	<keyword>Protective titer</keyword>
	<keyword>HBsAb</keyword>
	<keyword>Hepatitis B virus immune globulin</keyword>
	<keyword>Niuliva</keyword>
</DOC>